Osteopontin (OPN) Isoforms, Diabetes, Obesity, and Cancer; What Is One Got to Do with the Other? A New Role for OPN

Journal of Gastrointestinal Surgery

Volumn 19, Issue 4, 2015, Pages 639-650

  Sarosiek, Konrad ^a   Jones, Elizabeth ^a   Chipitsyna, Galina ^c   Al Zoubi, Mazhar ^a   Kang, Christopher ^a   Saxena, Shivam ^a   Gandhi, Ankit V ^a   Sendiky, Jocelyn ^b   Yeo, Charles J ^a   Arafat, Hwyda A ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Diabetes; Obesity; OPN; Osteopontin; Pancreatic ductal adenocarcinoma

Indexed keywords

ISOPROTEIN; OSTEOPONTIN;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS; FEMALE; HUMAN; MALE; MIDDLE AGED; OBESITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OSTEOPONTIN; PANCREATIC NEOPLASMS; PROTEIN ISOFORMS;

EID: 84925533529     PISSN: 1091255X     EISSN: 18734626     Source Type: Journal    
DOI: 10.1007/s11605-014-2735-6     Document Type: Article

References (41)

1. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure. Surgery. 2012;152(3 Suppl 1):S43-9. doi: 10.1016/j.surg.2012.05.020.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi: 10.3322/caac.20073.
3. Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. J Cell Biochem. 2005;95(4):649–656. doi: 10.1002/jcb.20461.
4. Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23(38):6365–6378. doi: 10.1038/sj.onc.1207751.
5. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(2):459–466. doi: 10.1158/1055-9965.EPI-04-0583.
6. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14(6):433–439. doi: 10.1016/j.semcancer.2004.06.006.
7. Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res. 2000;8(9):673–675. doi: 10.1038/oby.2000.86.
8. Pedersen M, Bruunsgaard H, Weis N, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev. 2003;124(4):495–502.
9. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: Role in cell signaling and cancer progression. Trends Cell Biol. 2006;16(2):79–87. doi: 10.1016/j.tcb.2005.12.005.
10. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3(3–4):311–322. doi: 10.1007/s12079-009-0068-0.
11. Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sørensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in crohn’s disease. Scand J Immunol. 2007;65(5):453–460. doi: 10.1111/j.1365-3083.2007.01908.x.
12. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006;17(6):463–474. doi: 10.1016/j.cytogfr.2006.09.010.
13. Gimba ER, Tilli TM. Human osteopontin splicing isoforms: Known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013;331(1):11–17. doi: 10.1016/j.canlet.2012.12.003.
14. Sullivan J, Blair L, Alnajar A, et al. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery. 2009;146(2):232–240. doi: 10.1016/j.surg.2009.03.036.
15. Siddiqui A, Jones E, Andrade D, et al. Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. Clinical Gastroentrology. In Press.
16. Lazar M, Sullivan J, Chipitsyna G, et al. Induction of monocyte chemoattractant protein-1 by nicotine in pancreatic ductal adenocarcinoma cells: Role of osteopontin. Surgery. 2010;148(2):298–309. doi: 10.1016/j.surg.2010.05.002.
17. Lazar M, Sullivan J, Chipitsyna G, et al. Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells. J Gastrointest Surg. 2010;14(10):1566–1577. doi: 10.1007/s11605-010-1338-0.
18. Sullivan J, Blair L, Alnajar A, et al. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol Histopathol. 2011 Jul;26(7):893–904.
19. Prince CW, Oosawa T, Butler WT, et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. Journal of Biological Chemistry. 1987;262(6):2900–2907.
20. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011;5(2):111–122. doi: 10.1007/s12079-011-0130-6.
21. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. doi: 10.1038/ncb1596.
22. Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate. 2012;72(15):1688–1699. doi: 10.1002/pros.22523.
23. Tilli TM, Franco VF, Robbs BK, et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011;9(3):280–293. doi: 10.1158/1541-7786.MCR-10-0463.
24. Baker BM, Chen CS. Deconstructing the third dimension: How 3D culture microenvironments alter cellular cues. J Cell Sci. 2012;125(Pt 13):3015–3024. doi: 10.1242/jcs.079509.
25. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8 (Suppl 2):S3. doi: 10.1186/ar1917.
26. Barber MD, Fearon KC, Ross JA. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond). 1999;96(1):83–87.
27. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456–469. doi: 10.1016/j.ccr.2011.03.009.
28. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia. 2005;48(6):1038–1050. doi: 10.1007/s00125-005-1764-9.
29. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813–823.
30. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1–38. doi: 10.1007/s10254-003-0012-2.
31. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. FASEB J. 2001;15(1):43–58. doi: 10.1096/fj.99-1003rev.
32. Wu Y, Jiang P, Lin Y, Chen S, Lin N, Li J. Expression of phosphorylated-STAT3 and osteopontin and their correlation in melanoma. J Huazhong Univ Sci Technolog Med Sci. 2009;29(2):246–250. doi: 10.1007/s11596-009-0223-0.
33. Zheng LM, Ojcius DM, Garaud F, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med. 1996;184(2):579–584.
34. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis. Clin Cancer Res. 1996;2(12):1969–1979.
35. Tanikawa T, Wilke CM, Kryczek I, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 2012;72(2):420–429. doi: 10.1158/0008-5472.CAN-10-4627.
36. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol. 1987;139(9):2977–2983.
37. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95(13):7556–7561.
38. Al-Zoubi M, Salem AF, Martinez-Outschoorn UE, et al. Creating a tumor-resistant microenvironment: Cell-mediated delivery of TNF-alpha completely prevents breast cancer tumor formation in vivo. Cell Cycle. 2013;12(3):480–490. doi: 10.4161/cc.23370.
39. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology. 2012;1(7):1074–1083. doi: 10.4161/onci.20897.
40. Keystone EC. Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: A review of longterm data. J Rheumatol. 2011;38(8):1552–1562. doi: 10.3899/jrheum.100995.
41. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–1050. doi: 10.1016/j.jaad.2010.09.734.